On Thursday, US regulators who approved the first of a new class of drugs for migraine prevention.
The United States Food and Drug Administration said it endorsed Aimovig for prevention of a migraine in adults, through monthly self-injections.
Aimovig is the first in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule involved in migraine attacks, the FDA said in a statement.
“Aimovig provides patients with a novel option for reducing the number of days with a migraine,” said Eric Bastings, a deputy director in the FDA’s Center for Drug Evaluation and Research.
“We need new treatments for this painful and often debilitating condition.”
Read More: Solar System has the 9th planet? It is, not Pluto!
A migraine is three times more common in women than in men and affects more than 10 percent of people worldwide.
The FDA issued its approval to California-based Amgen Inc, which has been collaborating with Swiss pharmaceutical firm Novartis to develop and commercialize treatments for a migraine and Alzheimer’s.
Aimovig is expected to be available to patients within one week and is listed at a price of $6,900 annually, Amgen said in a statement.
Post Your Comments